Myriad Genetics will discuss its Q2 2026 financial performance and business update on July 30, 2026.
Quiver AI Summary
Myriad Genetics, Inc. will host its second quarter 2026 earnings conference call on July 30, 2026, at 4:30 pm ET, following the release of its quarterly earnings after market close. The call will feature management discussing the company's financial performance and updates. Investors can listen to the call through a live webcast on the Investor Relations section of the Myriad website, and a registration is required for those wishing to participate by phone. Myriad Genetics focuses on molecular diagnostic testing and precision medicine, providing tests that help identify genetic risks and guide treatment decisions.
Potential Positives
- Myriad Genetics is positioned as a leader in molecular diagnostic testing and precision medicine, highlighting its significant role in the healthcare sector.
- The upcoming earnings conference call provides an opportunity for transparency on financial performance, which may enhance investor confidence.
- The release indicates a commitment to advancing health and well-being through genetic insights, showcasing the company's focus on innovation and patient care.
Potential Negatives
- There is no specific information regarding financial performance or guidance in the press release, which may lead to uncertainty among investors.
- The announcement of a scheduled earnings call could suggest the company has not achieved significant milestones that would warrant an earlier release of information.
- Failing to provide advance performance insights may indicate potential challenges the company is currently facing and reduce investor confidence.
FAQ
When is Myriad Genetics' second quarter 2026 earnings call scheduled?
Myriad Genetics' second quarter 2026 earnings call is scheduled for 4:30 pm ET on Thursday, July 30, 2026.
How can I access the Myriad Genetics earnings conference call?
You can access the call live via webcast on Myriad’s Investor Relations website at investor.myriad.com.
Will there be an opportunity to participate in the earnings call by telephone?
Yes, interested participants can register to receive a dial-in number and unique PIN to join the call.
Where can I find the archived webcast of the earnings call?
An archived version of the earnings call will be available on Myriad’s Investor Relations website after the call.
What does Myriad Genetics focus on in their services?
Myriad Genetics specializes in molecular diagnostic testing and precision medicine to enhance patient care and guide treatment decisions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MYGN Insider Trading Activity
$MYGN insiders have traded $MYGN stock on the open market 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
- S. LOUISE PHANSTIEL has made 3 purchases buying 104,507 shares for an estimated $494,722 and 0 sales.
- SAMRAAT S. RAHA (President and CEO) purchased 40,000 shares for an estimated $199,844
- RASHMI KUMAR sold 15,000 shares for an estimated $66,843
- PAUL BISARO purchased 7,500 shares for an estimated $27,637
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MYGN Revenue
$MYGN had revenues of $200.4M in Q1 2026. This is an increase of 2.3% from the same period in the prior year.
You can track MYGN financials on Quiver Quantitative's MYGN stock page.
You can access data on MYGN stock through the Quiver Quantitative API.
$MYGN Hedge Fund Activity
We have seen 95 institutional investors add shares of $MYGN stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 6,414,206 shares (-41.9%) from their portfolio in Q1 2026, for an estimated $28,863,927
- STATE STREET CORP removed 1,542,540 shares (-25.9%) from their portfolio in Q1 2026, for an estimated $6,941,430
- ACADIAN ASSET MANAGEMENT LLC added 1,322,441 shares (+134.1%) to their portfolio in Q1 2026, for an estimated $5,950,984
- HRT FINANCIAL LP added 1,317,451 shares (+281.0%) to their portfolio in Q1 2026, for an estimated $5,928,529
- JANE STREET GROUP, LLC added 1,148,114 shares (+2109.8%) to their portfolio in Q1 2026, for an estimated $5,166,513
- MARSHALL WACE, LLP added 1,081,456 shares (+4849.1%) to their portfolio in Q1 2026, for an estimated $4,866,552
- GLENVIEW CAPITAL MANAGEMENT, LLC added 824,571 shares (+18.0%) to their portfolio in Q1 2026, for an estimated $3,710,569
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MYGN Price Targets
Multiple analysts have issued price targets for $MYGN recently. We have seen 3 analysts offer price targets for $MYGN in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $5.5 on 05/06/2026
- Kyle Boucher from TD Cowen set a target price of $6.0 on 05/06/2026
- Lu Li from UBS set a target price of $6.0 on 02/24/2026
Full Release
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter of 2026.
A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com . To participate in the live conference call via telephone, please register here . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit
myriad.com
.
Investor Contact
Matt Scalo
(801) 584-3532
[email protected]
Media Contact
Andria Rosell
(385) 202-3510
[email protected]
